Personalised medicine targeting childhood leukaemia.

Acute lymphoblastic leukaemia (ALL), the most common form of childhood cancer, affects the blood and bone marrow. Almost 400 adults and children are diagnosed with ALL in Australia every year.

This project, sponsored by the Statewide Cancer Clinical Network, will build on the Queensland Myeloid Genomics Program funded in Round 2.

Targeted genomic tests will be used to provide rapid, comprehensive, and cost-effective analysis of acute leukaemias, with a focus on children’s leukaemias such as ALL. The tests will also help further improve the analysis of other acute leukaemias including acute myeloid leukaemia (AML).

Diagnostic data provided through genomic testing will support clinicians to make better informed treatment decisions regarding bone marrow transplantation, and the use of novel drugs such as tyrosine kinase inhibitors.

Project Investigators

Project leaders engage with and draw upon the expertise of partners within universities, research institutes and hospital and health services around Queensland.

Associate Professor Andrew Moore, Children’s Health Queensland Hospital and Health Service (lead)


other cancer projects